Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts

BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts

路透社路透社2026/11/09 22:31
Show original

- ** Video game publisher Take-Two Interactive (TTWO.O) saw its share price rise by about 4% in after-hours trading, reaching $216.2192.

** The company (link) raised its annual revenue and profit outlook (link) ahead of the highly anticipated launch of Grand Theft Auto VI.

** It expects total revenue for fiscal year 2027 to reach $7.98 billion to $8.18 billion, up from the previous forecast of $7.90 billion to $8.10 billion.

** The company raised the lower end of its full-year earnings guidance by 2 cents, now projecting earnings per share of $0.57 to $0.75.

** However, TTWO expects third-quarter bookings to fall short of analyst estimates.

** According to data compiled by London Stock Exchange Group (LSEG), third-quarter bookings are expected to be between $3.35 billion and $3.50 billion, while analysts on average expected $3.51 billion.

** Second-quarter total bookings fell 18% to $1.60 billion, missing the expected $1.67 billion.

** As of the previous market close, TTWO shares have fallen about 19% so far this year.


(To assist non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers' convenience. Reuters accepts no responsibility for any damage or loss resulting from the use of the automated translation function.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12